Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients.
Zazuli Z, Kos R, Veltman JD, Uyterlinde W, Longo C, Baas P, Masereeuw R, Vijverberg SJH, Maitland-van der Zee AH. Zazuli Z, et al. Among authors: baas p. Front Pharmacol. 2020 Jun 26;11:975. doi: 10.3389/fphar.2020.00975. eCollection 2020. Front Pharmacol. 2020. PMID: 32670072 Free PMC article.
Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, Smit A, Rikers C, van den Heuvel M. Uyterlinde W, et al. Among authors: baas c, baas p. Clin Lung Cancer. 2013 Sep;14(5):541-8. doi: 10.1016/j.cllc.2013.04.001. Epub 2013 Jul 5. Clin Lung Cancer. 2013. PMID: 23835165
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
de Vries R, Muller M, van der Noort V, Theelen WSME, Schouten RD, Hummelink K, Muller SH, Wolf-Lansdorf M, Dagelet JWF, Monkhorst K, Maitland-van der Zee AH, Baas P, Sterk PJ, van den Heuvel MM. de Vries R, et al. Among authors: baas p. Ann Oncol. 2019 Oct 1;30(10):1660-1666. doi: 10.1093/annonc/mdz279. Ann Oncol. 2019. PMID: 31529107 Free article.
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Joerger M, et al. Among authors: baas p. Cancer Chemother Pharmacol. 2012 Jan;69(1):25-33. doi: 10.1007/s00280-011-1670-4. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590444
Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M, Schouten RD, De Gooijer CJ, Baas P. Muller M, et al. Among authors: baas p. Expert Rev Anticancer Ther. 2017 May;17(5):399-409. doi: 10.1080/14737140.2017.1311791. Epub 2017 Apr 3. Expert Rev Anticancer Ther. 2017. PMID: 28338376 Review.
598 results